Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.
Rick Doblin, Recently Visited one of Psycheceutical's Labs.
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.
If we average out the two most recent price targets this month, we come out with a potential gain of 337% and that ain't...
Hidden Gem and a Monster in the Making? Beasley Broadcast Group (BBGI) $0.80
If They Simply Changed Their Name to Beasley Internet Group, it Could be Revalued 3-Fold Higher.
We attended their Investor Dinner in Boca Raton...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced...
Smart for Life (SMFL) Reports Revenue Increases 96.9% to $17.8 Million for 2022
Smart for Life Reports 2022 Financial Results and Provides Business Update
(Bolding by IA Editor)
BOCA RATON, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Smart for...
Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Think Equity, LLC (“Think Equity”)...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD)
Dicerna (DRNA) $3.30 to $38.25 up...
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.
The uncertainty created by SVB...